

Special Issue

New Advances in Pathogenesis and Treatment of HIV Infection: Molecular Insight and Preclinic Research

Message from the Guest Editors

Infection caused by human immunodeficiency virus (HIV) remains one of the most important challenges for researchers and requires the development of strategies and effective cures. The spectrum of diseases associated with HIV ranges from opportunistic infections and cancers to systemic physiological disorders such as encephalopathy and neurocognitive impairment. Over the last few years, much progress in controlling HIV infection has been made by highly active antiretroviral therapy (HAART). However, HAART neither eliminates the virus reservoirs in the form of latently infected cells nor completely reconstitutes the immune reactivity and physiological status. Furthermore, the causal relationships between the complex sets of viral and immunological processes that contribute to protection or disease pathogenesis remain poorly understood. The aim of this Special Issue is to publish high-quality research on the pathogenesis and treatment of HIV. This research will contribute to the development of new methodologies for analysis and therapy, and to the prediction of the functional restoration of the immune system and the health of the infected host.

Guest Editors

Prof. Dr. Alessandro Russo

Dr. Gabriella D'Ettorre

Dr. Ceccarelli Giancarlo

Deadline for manuscript submissions

closed (15 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/66350

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).